Company Research Report: DIAGAST

Company Overview

• Name: DIAGAST

• Mission: DIAGAST aims to facilitate the work of health professionals by ensuring speed and safety in blood grouping. Their core business is immuno-hematology, with a focus on innovation and human-centric operations.

• Founded: 1988

• Founder: No information is available

• Key People: No information is available

• Headquarters: 251, avenue Eugène Avinée, Parc Eurasanté, 59120 LOOS, France

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: DIAGAST is known globally in the field of transfusion medicine. It is renowned for its expertise in immuno-hematology and its innovative solutions in blood grouping.

Products

Core Offerings

1. ABTest Card®

• Description: A pre-transfusion control card.

• Key Features: Ensures ultimate safety in pre-transfusion testing.

2. Manual Plate

• Description: Disposable plates for manual immuno-hematology tests.

• Key Features: Facilitates various immuno-hematology tests with simplicity and efficiency.

3. I-MAG SCREEN

• Description: A panel of three magnetized erythrocytes for RAI (Research and Identification of Antibodies).

• Key Features: Provides accurate antibody screening using magnetized cells.

4. ABD PAD®

• Description: Blood group confirmation device.

• Key Features: Confirms blood group with ease and accuracy before transfusion.

5. QWALYS® 3 EVO

• Description: A comprehensive automation system for immuno-hematology.

• Key Features: Integrates various stages of blood analysis for automated and precise results.

6. M-TRAP® Technology

• Description: An innovative platform for manual techniques in blood testing.

• Key Features: Offers a modern alternative to traditional hemagglutination techniques.

Additional Product Lines

• OEM Solutions: Custom bulk concentrates and ready-to-use reagents tailored to specific client needs.

• Quality Controls: Internal and external products to ensure reliable test results.

Recent Developments

• March 2023: Obtained its first IVDR (In Vitro Diagnostic Regulation) certification for Class D products, specifically involving reagents for double blood group and phenotype determination on Beckman Coulter PK7300 and PK7400 systems.

• Guatemala Launch: Successful introduction of the QWALYS EVO system in the Guatemalan market.

• Safety Week Participation: DIAGAST actively participated in the "Semaine de la Sécurité des Patients" to promote awareness around patient safety and transfusion security.

Upcoming Events

• MEDLAB 2024: Participation in the 23rd edition of Medlab Middle East, scheduled for February 5-8, 2024, in Dubai.

Additional Notes

DIAGAST maintains a strong focus on R&D, ensuring their products and technologies remain at the forefront of transfusion medicine. With an emphasis on safety, innovation, and customer-specific solutions, DIAGAST continues to be a pivotal player in the immuno-hematology landscape.